News
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...
AOU data comprised electronic health records (EHRs) of 18,746 adult T2D patients (57% female) who initiated GLP‑1 RA, SGLT2i, or DPP4i therapies on or after January 2018.
New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.
Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...
LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.
Continuous Protein Sensor for Sarcopenia Management During GLP-1 RA Therapy Presented on Sunday, June 22 at 12:30 – 1:30 PM CT About the ADA's Scientific Sessions ...
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND ...
About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results